ARTICLE | Clinical News
COM completes enrollment in fibrillation Phase III
October 12, 2004 7:00 AM UTC
Cardiome (TSE:COM; CRME) completed enrollment of 420 patients with atrial fibrillation in the Phase III ACT-1 trial of its RSD1235 antiarrhythmic. The primary endpoint is acute conversion to normal he...